Pulmobiotics
The scientific team of Pulmobiotics, a company founded in 2020 at the Center for Genomic Regulation (CRG) in Barcelona, has started working on a 'living pill' to improve the efficacy of lung cancer treatment.
Pulmobiotics has raised €1.9M across 1 funding round from 1 investor, most recently a Seed round in Dec 2022. Based in Barcelona, Spain; active in Healthtech. Data as of 28 Oct 2026.
Barcelona, Spainwww.pulmobio.com ↗
Total raised
€1.9M
€1,900,000
Funding rounds
1
Investors
1
distinct backers
Active since
2022-12
latest 2022-12
Funding by year
EUR raised per yearPulmobiotics — funding by year — interactive chart.
Data table
| Pulmobiotics — funding by year | |
|---|---|
| 2022 | €1.9M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Seed
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-12-15 | Seed | €1.9M | European Innovation Council | View deal → |
Investors
1Related news
- Pulmobiotics obtiene 1,9M€ para desarrollar un nuevo tratamiento contra el cáncer de pulmónelreferente.es · 2022-12
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Jobandtalent€1.4BSpain · HRtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Perk (formerly TravelPerk)€1.1BSpain · Travel
Global coverage: FundingData